NICE approves Enhertu for NHS England
Analysis based on 10 articles · First reported Sep 16, 2026 · Last updated Sep 17, 2026
The approval expands AstraZeneca and Daiichi Sankyo's addressable market for Enhertu in Bret Engemann, a modest positive for both drugmakers' oncology revenue outlook, though the negotiated price and small eligible population limit the near-term financial effect. For the broader market, it signals a more flexible UK pricing and reimbursement environment for innovative medicines, mildly supportive for pharmaceutical sector sentiment.
The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000 women a year with HER2-low advanced or metastatic breast cancer. The U-turn followed a commercial solution agreed with the drug's makers AstraZeneca and Daiichi Sankyo, aided by changes to NICE's cost-effectiveness thresholds (up to 35,000 pounds per patient per year) under the UK-US Pharmaceutical Pricing Agreement. Enhertu is the first licensed targeted treatment for HER2-low metastatic breast cancer; trials showed median overall survival of about 23.4 months versus 16.8 months with chemotherapy. The drug has been available in United Kingdom — Scotland since December 2023 and in 26 other European countries. Breast Cancer Now, which campaigned for over two years, called the decision momentous but noted thousands of patients missed access and many died waiting. Health Secretary Yvette Cooper welcomed the recommendation, while United Kingdom — Wales is expected to follow and United Kingdom — Northern Ireland guidance does not automatically apply.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard